2-methylene-19-nor-(20s)-1,25-dihydroxyvitamin d3
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2007 (NCT00715676)
Timeline
Indications
Mechanism of action
- Vitamin D receptorAGONIST
VDR agonist
Chemistry & pharmacology
Loading structure…
SMILES
C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@H]1O- Mol. weight
- 416.65 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL605525 ↗
Also known as
- 2md
- 2md
- 2-methylene-19-nor-(20s)-1,25-dihydroxyvitamin d3
- dp001
- dp001
- dp001
- dp-001
- dp-001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01969656 | Phase 1 | Oct 22, 2013 | Deltanoid Pharmaceuticals |
| NCT01922843 | Phase 2 | Sep 1, 2013 | Deltanoid Pharmaceuticals, Harvard University |
| NCT01653379 | Phase 2 | Aug 1, 2012 | Deltanoid Pharmaceuticals, Harvard University |
| NCT00715676 | Phase 2 | Mar 1, 2007 | Deltanoid Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Deltanoid Pharmaceuticals | For profit | 4 | 4 | 2 | 2007 |
| Harvard University | Academic/Hospital | 2 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1